Cigna And Humana Revive Early Merger Talks After Year-Long Pause As Medicare Cost Pressure Looms
Cigna And Humana Revive Early Merger Talks After Year-Long Pause As Medicare Cost Pressure Looms
In a significant development in the health insurance industry, Cigna Group (NYSE:CI) has reinitiated discussions to merge with Humana Inc. (NYSE:HUM), potentially creating a giant in the sector.
在保險行業發生重大變化，Cigna集團（紐交所: CI）已重新啓動與Humana公司（紐交所: HUM）合併討論，有可能打造出該板塊的巨頭。
Talks, previously stalled over pricing disagreements, have resumed with a focus on a transformative consolidation that could reshape market dynamics.
先前因定價分歧而停滯不前的談判已經重新開始，重點放在顛覆性合併上，有望改變市場動態。
According to a Bloomberg report on Friday, the early talks about the merger would significantly expand Cigna's footprint in Medicare Advantage alongside its commercial insurance prowess while leveraging Humana's strong Medicare segment.
根據彭博社週五的報道，有關合並的初步談判將大幅擴張Cigna在Medicare Advantage領域的業務版圖，同時利用Humana強大的Medicare部門。
Also: US Federal Trade Commission Sues CVS Health, Cigna, UnitedHealth's Pharmacy Benefit Managers For Inflating Insulin Prices
此外：美國聯邦貿易委員會起訴CVS健康、Cigna、聯合健康的藥品福利管理員操縱胰島素價格。
Last year, both companies faced challenges as they navigated federal pressures to reduce Medicare costs, severely impacting Humana's market performance and valuation.
去年，這兩家公司在應對聯邦壓力降低Medicare成本時面臨挑戰，嚴重影響了Humana的市場表現和估值。
These resumed talks hint at a possible major realignment aiming to fortify their positions against competitors like UnitedHealth Group Inc (NYSE:UNH) and CVS Health Inc (NYSE:CVS).
這些恢復的談判暗示着一項可能的重大重組，旨在鞏固他們的地位，抵禦類似聯合健康集團（紐交所: UNH）和西維斯健康公司（紐交所: CVS）等競爭對手。
The merger discussions are still in the nascent stages, with no decisions made. Both companies declined to comment on the ongoing negotiations.
目前這些合併談判仍處於萌芽階段，尚未做出決定。兩家公司均拒絕就正在進行的談判發表評論。
A potential deal, estimated to be among the top five health insurance mergers, reflects a strategic shift in the industry focused on consolidation amid rising healthcare costs and stringent regulatory environments.
一筆預計進入前五名的保險合併交易顯示了行業在應對不斷上漲的醫療成本和嚴格的監管環境中的戰略轉變，重點關注整合。
This deal could not only stabilize Humana's declining Medicare enrollments but also enhance Cigna's capabilities in managing more comprehensive healthcare plans.
這項交易不僅可以穩定哈門那不斷下降的醫療保險登記人數，還可以增強Cigna在管理更全面醫療計劃方面的能力。
Furthermore, a merger could ease the competitive pressure from the rapidly growing sectors of the industry, providing a robust challenge to established giants.
此外，合併還可以減輕行業快速增長領域帶來的競爭壓力，對已建立的巨頭構成強有力挑戰。
Humana's stock value sharply declined due to lower-than-expected government reimbursements and increased demand for medical services. The merger is, therefore, potentially crucial for recovery and growth.
由於政府補償低於預期以及對醫療服務需求上升，哈門那的股價急劇下跌。因此，合併對於恢復和增長可能至關重要。
Price Action: CI stock is down 4.18% at $321.94, and HUM stock is up 0.88% at $269.50 at last check Monday.
價格走勢：CI股價下跌4.18%，報321.94美元，HUm股價上漲0.88%，報269.50美元。最後檢查時間爲週一。
- After Failed Confirmatory Trial, Gilead Withdraws US Accelerated Approval Of Trodelvy As Bladder Cancer Treatment.
- 在未能通過確認性試驗後，吉利德取消了特洛德替治療膀胱癌在美國的加速批准。
Photo via Shutterstock
圖片來自shutterstock。
譯文內容由第三人軟體翻譯。
